Announcement
James T. Joins Mavengity as a Medical Writer
With James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article
Posted in the last 24 hours
Fresh from the desks
Aerospace & Defense
Why the FAA Is Inspecting Hundreds of Boeing Jets That Have No Cracks
The FAA ordered inspections of roughly 471 U.S. 737 MAX jets for a structural crack that has not been found on a single one of them. Read closely, the order is not evidence of another Boeing failure, it's damage-tolerance engineering doing exactly what it's designed to do.
Compliance
Why Small Businesses Can't Find the Federal Cybersecurity Help That Already Exists
A new bipartisan Senate bill doesn't create any new cybersecurity tools for small businesses. It just orders a report on the federal help that already exists. The remedy it chose reveals that the real failure is awareness, not resources, a problem that recurs across nearly everything government tries to do.
Biotech Workforce
Boston Mastered Biotech's First Era. One Founder's Move to California Is a Question About Its Second
A Harvard-and-MIT-trained founder who fits Boston's exact entrepreneurial profile built his biotech company in California instead. One anecdote isn't a migration, but it points at a real risk, the source of biotech's regional advantage may be shifting from wet-lab biology to computation.
Public Health
One Year After the CDC Shooting, the Danger to Public Health Has Shifted From the Diseases It Fights to the Trust It Needs
A year after a gunman fired more than 180 rounds at CDC headquarters, killing a police officer, staff say they still feel targeted. The deepest damage wasn't the shattered windows, it was to the trust public health depends on to function at all.
Markets
The Polysilicon Tariff Sank Solar Stocks, Then Lifted Them. The Whipsaw Shows Why "Solar" Isn't One Industry
A new polysilicon tariff first sent First Solar and T1 Energy shares tumbling, then sent them jumping after the companies voiced support. The same policy read as a cost and then as protection, because solar is a value chain with opposed interests, not one industry.
Investing
Rigetti's Earnings Are the Wrong Thing to Analyze. A Quantum Stock Is an Option on a Breakthrough, Not a Business
Rigetti posted 183% revenue growth and a $52.6 million loss, and the stock fell anyway despite meeting estimates. Judged as a business the quarter is a paradox. Judged as a long-dated option on a technological breakthrough, everything about it, including the drop, makes sense.
Consumer Trends
The Money Hacks That Work All Share One Secret: They Let You Use Less Willpower, Not More
Automation, friction, defaults, and precommitment all work through the same mechanism, moving the saving decision out of the tired, tempted moment where willpower fails. The hacks that don't share that mechanism, vision boards and mantras, quietly fizzle out.
Science Policy
The NIH Plans to Bar Visa-Holding Scientists From a Career-Making Grant. The Real Cost Is Retention, and It's Easy to Miss
The NIH plans to close its K99/R00 "Pathway to Independence" award to scientists on temporary visas, removing one of the few federal bridges from postdoc to independent faculty for international researchers. The policy has a real case behind it, and a cost that is real, delayed, and easy to miss.
Corporate Strategy
Atlassian Went From Feared "AI Victim" to "AI Beneficiary" in One Quarter. The Reason Is Its Data, Not Its Software
Atlassian's stock jumped roughly 30% after Bank of America reversed course and called it an AI beneficiary rather than an AI victim. The reason is a general lesson for software companies, AI commoditizes features but makes proprietary data more valuable.
Announcements
News from Mavengity
Browse by topic
Where would you like to start?
Every article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Insurance
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceMortgage
Rates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgagePersonal Finance
Budgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceLegal
Contracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealthcare & Medical
Health coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse Healthcare
Why Mavengity
Editorial standards you can check
Independently researched
We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
Plain-English explanations
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
Straight, not slanted
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Written for readers, not lenders
Mavengity is reader-supported and editorially independent from the products we cover.